Alessandro Sticchi

In this interview, Alex Sticchi speaks with Fabien Praz and Michael Borger, co-chairs of the 2025 ESC/EACTS Valvular Guidelines Task Force. They discuss the major updates, including the central role of multimodality imaging, the lowered age threshold for TAVI, the distinction between atrial and ventricular secondary...

Alex Sticchi provides his take on the new ESC Valvular Guidelines presented at the ESC Congress 2025 in Madrid.

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

Explore the latest innovations in transcatheter aortic valve implantation (TAVI) devices with a focus on coronary protection strategies, cerebral embolic protection integration, management of ventricular migration, and overcoming anatomical challenges such as bicuspid and rheumatic valve disease using novel platforms.

Explore the multifaceted challenges in patients undergoing mitral TEER when additional mitral and tricuspid pathologies coexist. This session reviews data from the EXPANDed studies on tricuspid regurgitation post-mitral TEER, one-year outcomes based on cardiac damage extent, pulmonary hypertension dynamics, and the long-term mortality causes in this...

The objective of this study was to validate standardised clinical criteria for BVD and evaluate its association with mortality and rehospitalisation, thereby guiding optimal valve selection in clinical practice.

Alex Sticchi interviews Saibal Kar about the two-year results of the Triluminate pivotal trial, unveiled at ACC.25 in Chicago.

After revisiting the one-year findings and outlining the study design, Saibal Kar highlights key takeaways: at two years, TriClip therapy significantly reduced heart failure hospitalisations compared to medical...

This study demonstrates that OCT-defined TCFA is a superior prognostic marker compared to μQFR for assessing NCLs in AMI patients.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Immerse yourself in a captivating collection of featured cases showcasing the latest advances in transcatheter tricuspid valve interventions. Witness groundbreaking techniques, including the first TTVR designed to reduce afterload mismatch, the management of atrial embolization, and the use of intracardiac echocardiography. Explore complex anatomies, failed prior...

Alessandro Sticchi provides his take on the OPTION Trial presented at AHA 2024 in Chicago.

Stay up to date with what is new and hot in interventional cardiology at #AHA24 in Chicago.

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.

Simultaneous publication in European Heart Journal, ehae578

The review aims to address the unmet needs in heart failure (HF) management, particularly in patients where structural heart disease coexists with HF and limits the effectiveness of guideline-directed medical therapy (GDMT).

Alex Sticchi provides his take on the OCCUPI trial presented by Kim Byeong-Keuk at the ESC Congress 2024 in London.

Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.

What was new and hot in interventional cardiology at #ESCCongress 2024!

The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.

Alex Sticchi provides his take on the trials which were presented at New York Valves 2024, offering a concise summary, a short description and final thoughts. 

This session delves into the management of calcified coronary lesions, presenting various techniques and tools to address this common challenge. It covers topics such as the use of drug-coated balloons, rotational atherectomy, intravascular lithotripsy, and high-pressure non-compliant balloons. The session also includes a meta-analysis on the...

It is now understood that ischemia is not the only risk to consider, as bleeding also plays a significant role. This is why de-escalation is now recommended for patients with complex PCI, as all de-escalation strategies reduce bleeding risk. Discover more about the three different de-escalation...

This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.

Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.

Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24

Alessandro Sticchi interviews David E. Kandzari about the results of the Target Bp I Randomized Trial which he presented at ACC.24.

The trial reports mixed results on nerve ablation for high blood pressure with a modest but statistically significant difference in lowered blood pressure at 3 months,...

Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk randomized trial, presented at the #TCT23 Congress.
The analysis reveals comparable outcomes for TAVI and SAVR, with nuanced differences favouring each approach. Prof. Leon emphasizes the importance of long-term data...

This study, based on extensive real-world data, aimed to assess mortality rates across different untreated AS severities and AS treatment rates.